Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Pipeline Review, H2 2017’, provides an overview of the Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)

The report reviews pipeline therapeutics for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) therapeutics and enlists all their major and minor projects

The report assesses Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Aeolus Pharmaceuticals Inc

Angion Biomedica Corp

Atox Bio Ltd

AVM Biotechnology LLC

BCN Biosciences LLC

Bolder Biotechnology Inc

Cellerant Therapeutics Inc

Cellphire Inc

Chrysalis BioTherapeutics Inc

Cleveland BioLabs Inc

Daiichi Sankyo Co Ltd

FirstString Research Inc

Foresee Pharmaceuticals LLC

Galera Therapeutics Inc

Genzyme Corp

GNI Group Ltd

Humanetics Corp

Insys Therapeutics Inc

Meabco A/S

Medesis Pharma SA

Neumedicines Inc

Nohla Therapeutics Inc

Onconova Therapeutics Inc

Original BioMedicals Co Ltd

PharmaIN Corp

Pluristem Therapeutics Inc

RDD Pharma Ltd

RedHill Biopharma Ltd

RxBio Inc

Shuttle Pharmaceuticals LLC

SK Chemicals Co Ltd

Soligenix Inc

Synedgen Inc

Tonix Pharmaceuticals Holding Corp

TSRL Inc

viDA Therapeutics Inc

Windtree Therapeutics Inc

Table of Contents

Table of Contents

Table of Contents 2

Introduction 5

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Overview 6

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Therapeutics Development 7

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Therapeutics Assessment 18

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Companies Involved in Therapeutics Development 28

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Drug Profiles 44

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Dormant Projects 188

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Discontinued Products 194

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Product Development Milestones 195

Appendix 206

List of Tables

List of Tables

Number of Products under Development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome), H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Products under Development by Companies, H2 2017 (Contd..2), H2 2017

Products under Development by Companies, H2 2017 (Contd..3), H2 2017

Products under Development by Universities/Institutes, H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Pipeline by Aeolus Pharmaceuticals Inc, H2 2017

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Pipeline by Angion Biomedica Corp, H2 2017

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Pipeline by Atox Bio Ltd, H2 2017

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Pipeline by AVM Biotechnology LLC, H2 2017

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Pipeline by BCN Biosciences LLC, H2 2017

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Pipeline by Bolder Biotechnology Inc, H2 2017

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Pipeline by Cellerant Therapeutics Inc, H2 2017

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Pipeline by Cellphire Inc, H2 2017

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Pipeline by Chrysalis BioTherapeutics Inc, H2 2017

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Pipeline by Cleveland BioLabs Inc, H2 2017

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Pipeline by Daiichi Sankyo Co Ltd, H2 2017

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Pipeline by FirstString Research Inc, H2 2017

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Pipeline by Foresee Pharmaceuticals LLC, H2 2017

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Pipeline by Galera Therapeutics Inc, H2 2017

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Pipeline by Genzyme Corp, H2 2017

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Pipeline by GNI Group Ltd, H2 2017

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Pipeline by Humanetics Corp, H2 2017

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Pipeline by Insys Therapeutics Inc, H2 2017

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Pipeline by Meabco A/S, H2 2017

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Pipeline by Medesis Pharma SA, H2 2017

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Pipeline by Neumedicines Inc, H2 2017

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Pipeline by Nohla Therapeutics Inc, H2 2017

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Pipeline by Onconova Therapeutics Inc, H2 2017

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Pipeline by Original BioMedicals Co Ltd, H2 2017

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Pipeline by PharmaIN Corp, H2 2017

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Pipeline by Pluristem Therapeutics Inc, H2 2017

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Pipeline by RDD Pharma Ltd, H2 2017

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Pipeline by RedHill Biopharma Ltd, H2 2017

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Pipeline by RxBio Inc, H2 2017

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Pipeline by Shuttle Pharmaceuticals LLC, H2 2017

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Pipeline by SK Chemicals Co Ltd, H2 2017

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Pipeline by Soligenix Inc, H2 2017

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Pipeline by Synedgen Inc, H2 2017

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Pipeline by Tonix Pharmaceuticals Holding Corp, H2 2017

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Pipeline by TSRL Inc, H2 2017

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Pipeline by viDA Therapeutics Inc, H2 2017

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Pipeline by Windtree Therapeutics Inc, H2 2017

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Dormant Projects, H2 2017

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Dormant Projects, H2 2017 (Contd..1), H2 2017

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Dormant Projects, H2 2017 (Contd..2), H2 2017

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Dormant Projects, H2 2017 (Contd..3), H2 2017

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Discontinued Products, H2 2017

List of Figures

List of Figures

Number of Products under Development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome), H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Number of Products by Top 10 Targets, H2 2017

Number of Products by Stage and Top 10 Targets, H2 2017

Number of Products by Top 10 Mechanism of Actions, H2 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017

Number of Products by Top 10 Routes of Administration, H2 2017

Number of Products by Stage and Top 10 Routes of Administration, H2 2017

Number of Products by Top 10 Molecule Types, H2 2017

Number of Products by Stage and Top 10 Molecule Types, H2 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports